A population-based study of racial/ethnic disparities in cancer survival among adolescents and young adults.

Authors

null

Meryl Colton

University of Colorado School of Medicine, Aurora, CO

Meryl Colton , Adam L. Green

Organizations

University of Colorado School of Medicine, Aurora, CO, Children's Hospital Colorado, Aurora, CO

Research Funding

Other

Background: Disparities in cancer survival have been demonstrated between racial and ethnic groups. Several mechanisms could be involved, including differences in stage at presentation, treatment differences, and biological variation. Racial/ethnic disparities have not been comprehensively evaluated in adolescents and young adults (AYA) (age 15-29), a population at particular risk for disparities in socioeconomic status (SES) and delayed diagnosis. Methods: We utilized the Surveillance, Epidemiologic and End Results (SEER) 18 database to calculate hazard ratios (HR) of death within two years of diagnosis for Hispanic White (HW), Non-Hispanic Black (NHB), and Hispanic Black (HB) compared to Non-Hispanic White (NHW) individuals between the ages of 15 and 29 for each ICCC group. We then compared crude HR and HR adjusted for insurance status and/or stage at diagnosis to explore the influence of these factors. Results: HW, NHB and/or HB AYA were found to have significantly higher risk of death than NHW AYA for several cancer types. These associations were only partially attenuated after controlling for insurance status and stage at diagnosis (Table). Conclusions: Racial and ethnic disparities in survival exist among AYA in many cancer types. These differences are partially, but not fully, explained by insurance status and stage at presentation, suggesting influences of both biology and SES on the diagnostic and treatment processes. Further work should explore the mechanisms of these disparities.

Hazard ratios (HR) and 95% confidence intervals (95%CI) of HW and NHB AYA versus reference (NHW).

HR95%CI
Leukemia
    HW1.15(1.03, 1.29)
    NHB1.05(0.88, 1.25)
Lymphoma
    HW1.28(1.16, 1.40)
    NHB1.07(0.96, 1.2)
Brain tumors
    HW1.26(1.09, 1.46)
    NHB0.91(0.73, 1.13)
Renal tumors
    HW0.92(0.67, 1.28)
    NHB1.43(1.06, 1.94)
Hepatic tumors
    HW1.77(1.13, 2.76)
    NHB1.76(1.08, 2.87)
Bone tumors
    HW0.92(0.73, 1.16)
    NHB0.61(0.44, 0.86)
Soft tissue sarcomas
    HW1.19(1.03, 1.38)
    NHB1.23(1.11, 1.51)
Germ cell tumors
    HW1.27(1.17, 1.39)
    NHB1.16(0.96, 1.41)
Other malignant epithelial neoplasms
    HW1.15(1.08, 1.23)
    NHB1.13(1.04, 1.23)

Model adjusted for stage at presentation and insurance status.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Health Services Research and Quality of Care

Track

Health Services Research and Quality of Care

Sub Track

Access to Care

Citation

J Clin Oncol 34, 2016 (suppl; abstr 6557)

DOI

10.1200/JCO.2016.34.15_suppl.6557

Abstract #

6557

Poster Bd #

44

Abstract Disclosures

Similar Abstracts

First Author: Kekoa A. Taparra

First Author: Stephanie M Smith